Findings from MINT will be presented at the American Academy of Neurology Annual Meeting on April 8, 2025, in San Diego.

No swallow or voice evaluation or treatment were offered to 83.1% of all individuals with myasthenia gravis, 53% of patients with myasthenia gravis and any speech/swallow dysfunction, 43.8% who ...

The company, currently valued at $692 million, is preparing for several significant clinical trial readouts over the next 18 months, including a Phase 2 proof of concept in Myasthenia Gravis (MG), a ...

Upcoming data readouts for betoklamab in myasthenia gravis and CIDP are crucial for ... And so, and then just taking the next step, how do you see broader potential for brepacitinib speak to ...

Upcoming data readouts for betoklamab in myasthenia gravis and CIDP are crucial for Roivant’s strategic ... And so, and then just taking the next step, how do you see broader potential for ...

Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia gravis (gMG), one of two drugs that the company hopes will shake up the ...

Look ahead to this year's Muscular Dystrophy Association (MDA) meeting, which will feature discussions on the latest gene therapies, clinical trial data, policy considerations, and more in the realm ...

MUMBAI, India and WALTHAM, Mass., March 9, 2025 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE ...

over 6000 assets (including all Forex pairs, Cryptocurrencies, Commodities, Indices and US stocks) unique interbank rates extensive historic data the option to save your configuration Here below ...

Here below you have a complete description of its most interesting features and benefits so you can make the most of it. The majority of other information websites display prices of a single ...

Send us a tip using our anonymous form. A daily briefing on what matters in the music industry ...